Artrya signs US$500,000 deal with HonorHealth
Key points
- Artrya signed a five-year commercial agreement with Arizona Health System HonorHealth worth at least US$500,000.
- HonorHealth becomes the company’s fifth U.S. commercial customer and its first inbound client outside prior study groups.
- Artrya aims to expand U.S. customer acquisition and deploy its Salix cloud platform across nine acute-care hospitals.
Artrya (ASX:AYA) executed a five-year commercial agreement with HonorHealth worth a minimum of US$500,000 to expand its U.S. software footprint.
The contract follows the October deal with Huntsville Hospital Health System and marks Artrya’s first inbound customer outside its foundation and research partners.
"The HonorHealth agreement is another major step forward in our U.S. commercial roll-out and, importantly, represents our first inbound U.S. customer," said Artrya Co-Founder and CEO John Konstantopoulos.
The minimum US$500,000 fee covers Salix Coronary Anatomy, while two other modules will generate extra per-scan revenue pending regulatory clearance.
Following the announcement, the Artrya share price was up at $3.44.
Artrya develops artificial intelligence software that analyses coronary CT scans to help clinicians assess heart disease.
The company previously signed U.S. deals with Huntsville, Tanner Health, Northeast Georgia Health System, and Cone Health while joining the S&P/ASX 300 index.
Frequently asked questions
More from Australia
Tamboran delivers first Beetaloo gas sales worth US$1.8M
Cochlear reaffirms $330–350M profit guidance
Imricor Q3 revenue surges 437% to US$188,000
Accent Group reports 3.9% drop in FY27 retail sales
BHP restructures Australian iron ore unit after cutting 300 jobs
Clarity Pharmaceuticals wins FDA breakthrough designation for 64Cu-SAR-bisPSMA
